TY - JOUR
T1 - Current state of quality of life and patient-reported outcomes research
AU - 5th EORTC Quality of Life in Cancer Clinical Trials Conference Faculty
AU - Bottomley, Andrew
AU - Reijneveld, Jaap C.
AU - Koller, Michael
AU - Flechtner, Henning
AU - Tomaszewski, Krzysztof A.
AU - Greimel, Eva
AU - Ganz, Patricia A.
AU - Ringash, Jolie
AU - O'Connor, Daniel
AU - Kluetz, Paul G.
AU - Tafuri, Giovanni
AU - Grønvold, Mogens
AU - Snyder, Claire
AU - Gotay, Carolyn
AU - Fallowfield, Dame Lesley
AU - Apostolidis, Kathi
AU - Wilson, Roger
AU - Stephens, Richard
AU - Schünemann, Holger
AU - Calvert, Melanie
AU - Holzner, Bernhard
AU - Musoro, Jammbe Z.
AU - Wheelwright, Sally
AU - Martinelli, Francesca
AU - Dueck, Amylou C.
AU - Pe, Madeline
AU - Coens, Corneel
AU - Velikova, Galina
AU - Kuliś, Dagmara
AU - Taphoorn, Martin J. B.
AU - Darlington, Anne-Sophie
AU - Lewis, Ian
AU - van de Poll-Franse, Lonneke
PY - 2019/11/1
Y1 - 2019/11/1
N2 - The 5th EORTC Quality of Life in Cancer Clinical Trials Conference presented the current state of quality of life and other patient-reported outcomes (PROs) research from the perspectives of researchers, regulators, industry representatives, patients and patient advocates and health care professionals. A major theme was the assessment of the burden of cancer treatments, and this was discussed in terms of regulatory challenges in using PRO assessments in clinical trials, patients’ experiences in cancer clinical trials, innovative methods and standardisation in cancer research, innovative methods across the disease sites or populations and cancer survivorship. Conferees demonstrated that PROs are becoming more accepted and major efforts are ongoing internationally to standardise PROs measurement, analysis and reporting in trials. Regulators are keen to collaborate with all stakeholders to ensure that the right questions are asked and the right answers are communicated. Improved technology and increased flexibility of measurement instruments are making PROs data more robust. Patients are being encouraged to be patient partners. International collaborations are essential, because this work cannot be accomplished on a national level.
AB - The 5th EORTC Quality of Life in Cancer Clinical Trials Conference presented the current state of quality of life and other patient-reported outcomes (PROs) research from the perspectives of researchers, regulators, industry representatives, patients and patient advocates and health care professionals. A major theme was the assessment of the burden of cancer treatments, and this was discussed in terms of regulatory challenges in using PRO assessments in clinical trials, patients’ experiences in cancer clinical trials, innovative methods and standardisation in cancer research, innovative methods across the disease sites or populations and cancer survivorship. Conferees demonstrated that PROs are becoming more accepted and major efforts are ongoing internationally to standardise PROs measurement, analysis and reporting in trials. Regulators are keen to collaborate with all stakeholders to ensure that the right questions are asked and the right answers are communicated. Improved technology and increased flexibility of measurement instruments are making PROs data more robust. Patients are being encouraged to be patient partners. International collaborations are essential, because this work cannot be accomplished on a national level.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85072582660&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/31561134
U2 - https://doi.org/10.1016/j.ejca.2019.08.016
DO - https://doi.org/10.1016/j.ejca.2019.08.016
M3 - Article
C2 - 31561134
SN - 0959-8049
VL - 121
SP - 55
EP - 63
JO - European journal of cancer (Oxford, England
JF - European journal of cancer (Oxford, England
ER -